Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CRHBP | P24387 | 2/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HCN4 | Q9Y3Q4 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15496992 | 0.90 | LMNA (0.33) | LMNATP53CRHBPCRHR2THRB | |
| SCHEMBL11989201 | 0.84 | MEN1 (0.37) | HCN4MAPT | |
| SCHEMBL22967931 | 0.82 | MEN1 (0.35) | MAPT | |
| SCHEMBL18177230 | 0.80 | KCNH2 (0.33) | — | |
| SCHEMBL15081065 | 0.79 | CRHBP (0.46) | LMNACRHBPCRHR2THRBTDP1 | |
| SCHEMBL22958206 | 0.79 | CRHBP (0.46) | LMNACRHBPCRHR2THRBTDP1 | |
| SCHEMBL22967657 | 0.78 | MEN1 (0.32) | MAPT | |
| SCHEMBL16945977 | 0.76 | CRHBP (0.43) | LMNACRHBPCRHR2THRBTDP1 | |
| SCHEMBL22967418 | 0.76 | — | — | |
| SCHEMBL12513920 | 0.76 | CRHBP (0.44) | LMNACRHBPCRHR2THRBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11911371-B2 | Pyridine and pyrazine derivative for the treatment of chronic bronchitis | NOVARTIS AG (CH) | 2024-02-27 | — | — | US | disclosed |
| US-11911371-B2 | Pyridine and pyrazine derivative for the treatment of chronic bronchitis | NOVARTIS AG (CH) | 2024-02-27 | — | — | US | disclosed |
| US-20200383960-A1 | Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis | NOVARTIS AG (CH) | 2020-12-10 | — | — | US | disclosed |
| US-20190262324-A1 | Pyridine and Pyrazine Derivative for the Treatment of CF | NOVARTIS AG (CH) | 2019-08-29 | — | — | US | disclosed |
| US-RE46757-E1 | Pyridine and pyrazine derivative for the treatment of CF | NOVARTIS AG (CH) | 2018-03-20 | — | — | US | disclosed |
| US-20170071919-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | NOVARTIS AG (CH) | 2017-03-16 | — | — | US | disclosed |
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | AVALON PHARMACEUTICALS | 2011-07-21 | — | — | US | disclosed |
| US-20100249111-A1 | MULTI-RING COMPOUNDS AND USES THEREOF | AVALON PHARMACEUTICALS (US) | 2010-09-30 | — | — | US | disclosed |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | AVALON PHARMACEUTICALS | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200383960-A1 | Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis | CFTR, OPRK1, CHRM3 | LMNA 4571/4885TP53 385/4885CRHBP 3049/4885 |
| US-20190262324-A1 | Pyridine and Pyrazine Derivative for the Treatment of CF | CFTR, OPRK1, OPRD1 | LMNA 4666/4885TP53 370/4885CRHBP 2618/4885 |
| US-20100249111-A1 | MULTI-RING COMPOUNDS AND USES THEREOF | TP53, BCOR, HPGDS | LMNA 3158/4885TP53 1/4885CRHBP 2478/4885 |
| US-11911371-B2 | Pyridine and pyrazine derivative for the treatment of chronic bronchitis | CFTR, OPRK1, CHRM3 | LMNA 4454/4885TP53 350/4885CRHBP 2651/4885 |
| US-20170071919-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | CFTR, OPRK1, OPRD1 | LMNA 4666/4885TP53 370/4885CRHBP 2618/4885 |
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | HPGDS, HPGD, DPYD | LMNA 2809/4885TP53 7/4885CRHBP 485/4885 |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | HPGDS, HPGD, DPYD | LMNA 2809/4885TP53 7/4885CRHBP 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.